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factor.BACKGROUND & AIMS: Many patients with inflammatory
bowel disease (IBD) fail to respond to anti–tumor necrosis
factor (TNF) agents such as infliximab and adalimumab, and
etanercept is not effective for treatment of Crohn’s disease.
Activated matrix metalloproteinase 3 (MMP3) and MMP12,
which are increased in inflamed mucosa of patients with IBD,
have a wide range of substrates, including IgG1. TNF-
neutralizing agents act in inflamed tissues; we investigated
the effects of MMP3, MMP12, and mucosal proteins from IBD
patients on these drugs. METHODS: Biopsy specimens from
inflamed colon of 8 patients with Crohn’s disease and 8 patients
with ulcerative colitis, and from normal colon of 8 healthy in-
dividuals (controls), were analyzed histologically, or homoge-
nized and proteins were extracted. We also analyzed sera from
29 patients with active Crohn’s disease and 33 patients with
active ulcerative colitis who were candidates to receive inflix-
imab treatment. Infliximab, adalimumab, and etanercept were
incubated with mucosal homogenates from patients with IBD
or activated recombinant human MMP3 or MMP12 and
analyzed on immunoblots or in luciferase reporter assays
designed to measure TNF activity. IgG cleaved by MMP3 or
MMP12 and antihinge autoantibodies against neo-epitopes on
cleaved IgG were measured in sera from IBD patients who
subsequently responded (clinical remission and complete
mucosal healing) or did not respond to infliximab. RESULTS:
MMP3 and MMP12 cleaved infliximab, adalimumab, and eta-
nercept, releasing a 32-kilodalton Fc monomer. After MMP
degradation, infliximab and adalimumab functioned as F(ab’)2
fragments, whereas cleaved etanercept lost its ability
to neutralize TNF. Proteins from the mucosa of patients with
IBD reduced the integrity and function of infliximab, adalimu-
mab, and etanercept. TNF-neutralizing function was restored
after incubation of the drugs with MMP inhibitors. Serum
levels of endogenous IgG cleaved by MMP3 and MMP12,
and antihinge autoantibodies against neo-epitopes of cleaved
IgG, were higher in patients who did not respond to treatment
vs responders. CONCLUSIONS: Proteolytic degradation may
contribute to the nonresponsiveness of patients with IBD to
anti-TNF agents.Most current article
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http://dx.doi.org/10.1053/j.gastro.2015.07.002Keywords: Therapy; Inflammation; UC; CD.iologic therapies with agents that neutralize tumorBnecrosis factor (TNF) have revolutionized the treat-
ment of human chronic inflammatory diseases.1 Respon-
siveness, however, is difficult to predict, and there may be
differences in efficacy and mode of action between different
agents.2–4 In particular, infliximab and adalimumab are
monoclonal IgG1 antibodies, and etanercept is a dimeric
p75 TNF receptor–IgG Fc fusion protein.5,6 The fact that eta-
nercept is not helpful in Crohn’s disease,7 but is effective in
rheumatoid arthritis and psoriasis,8,9 remains unexplained.
Moreover, information on the bioavailability of drugs in
inflamed tissues, where TNF-neutralizing agents are expect-
ed to exert their action, is completely lacking.
Increased tissue levels of proteases, including matrix
metalloproteinases (MMPs), are seen in inflammatory bowel
disease (IBD), rheumatoid arthritis, asthma, and chronic
obstructive pulmonary disease.10–14 In particular, MMP3,
MMP12, and MMP9 are highly up-regulated in the inflamed
gut of IBD patients.12–14 Interestingly, IgG1 has a Thr-His
human neutrophil elastase cleavage site in the upper hinge,
and there is a Pro-Glu scissile bond susceptible to cleavage by
MMP3 and MMP12 in the lower hinge.15,16 Trastuzumab, a
monoclonal antibody used in the treatment of breast cancer,
can be degraded by a number of proteolytic enzymes, with
consequent reduction of its immune effector functions.17
Moreover, cleaved IgG has been detected within squamous
cell carcinomawith a predominant localization at the invasive
front, a site particularly rich in proteases.18
We therefore have examined the effects of MMPs and
mucosal homogenates from inflamed human bowel on the
integrity and function of commonly used TNF-neutralizing
agents.
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Patients
This study was approved by the London City and Hackney
Ethics Committee, and informed consent was obtained from all
subjects. To assess the effect of proteins from human gut mu-
cosa on the integrity and function of TNF-neutralizing agents,
perendoscopic biopsy specimens from the inflamed colon of 8
Crohn’s disease and 8 ulcerative colitis patients (Table 1) and
from the normal colon of 8 healthy control (HC) subjects were
collected and processed for routine histology or protein
extraction after homogenization. Sera from 29 active Crohn’s
disease and 33 active ulcerative colitis patients, who were
candidates to receive infliximab treatment, were collected.
Responsiveness to infliximab treatment was defined as the
concomitant presence of clinical remission and complete
mucosal healing19 at the first endoscopic examination after
starting treatment.Protein Extraction
Biopsy specimens were placed in phosphate-buffered saline
(PBS) (Oxoid, Ltd, Basingstoke, UK) and homogenized by son-
ication. Endogenous IgG was removed from the mucosal pro-
teins by the Protein G SpinTrap (GE Healthcare, Little Chalfont,Table 1.Clinical Features of 16 IBD Patients
CD (n ¼ 8) UC (n ¼ 8)
Median age, y (range) 28 (20–55) 30.5 (22–63)
Male/female (%) 5/3 (62.5/37.5) 4/4 (50/50)
Median duration of disease, y (range) 4 (0.5–11) 3 (0–15)
Extent of disease
Ileocolon–CD (%) 4 (50) NA
Colon–CD (%) 4 (50) NA
Left-sided colitis–UC (%) NA 5 (62.5)
Pancolitis–UC (%) NA 3 (37.5)
Disease behavior
Nonstricturing nonpenetrating–CD
(%)
8 (100) NA
Stricturing–CD (%) 0 (0) NA
Penetrating–CD (%) 0 (0) NA
Clinical disease activity
Mild (%) 0 (0) 0 (0)
Moderate (%) 3 (37.5) 2 (25)
Severe (%) 5 (62.5) 6 (75)
Grading of histologic inflammation
Mild (%) 0 (0) 0 (0)
Moderate (%) 0 (0) 1 (12.5)
Severe (%) 8 (100) 7 (87.5)
Treatment
None 1 (12.5) 2 (25)
Mesalamine (%) 2 (25) 4 (50)
Corticosteroids (%) 3 (37.5) 4 (50)
Immunosuppressants
Azathioprine/6-mercaptopurine
(%)
2 (25) 3 (37.5)
Methotrexate (%) 1 (12.5) 0 (0)
Corticosteroids þ
immunosuppressants (%)
3 (37.5) 3 (37.5)
CD, Crohn’s disease; UC, ulcerative colitis.
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2 mg/mL by dilution in PBS.
MMP Activity Assay
MMP3/MMP12 activity in IBD and HC homogenates was
measured using the fluorescence resonance energy transfer–
based Sensolyte 520 MMP12 assay kit from AnaSpec, Inc
(Fremont, CA).
Cleavage Reactions
Upon activation, recombinant human MMP3, MMP12, and
MMP9 (R&D Systems, Abingdon, UK) were co-incubated for 24
hours with infliximab (Remicade; Schering-Plough, Welwyn
Garden City, UK), adalimumab (Humira; Abbott Laboratories,
Chicago, IL), or etanercept (Enbrel; Wyeth, Maidenhead, UK) to
evaluate their effect on drug integrity and function. Moreover,
infliximab, adalimumab, or etanercept was co-incubated for 24
hours with either PBS only or with IBD or HC mucosal ho-
mogenates. In parallel, cleavage reactions were performed
with the addition of the MMP inhibitors marimastat (Sigma-
Aldrich, Poole, UK) or UK370106 (Santa Cruz Biotechnology,
Dallas, TX). Details of cleavage reactions are reported in the
Supplementary Materials and Methods section. Cleavage re-
action products then were stored at -70C until further
analysis.
Immunoblotting
The effect of proteases on the integrity of TNF-neutralizing
agents was assessed by immunoblotting under denaturing
conditions. Rabbit anti-human immunoglobulin Fc antibody
(Fisher Scientific UK, Loughborough, UK) or rabbit anti-human
immunoglobulin k light-chain antibody (Abcam, Cambridge,
UK) were used as primary antibodies. Bands were quantified by
densitometry using ImageJ software (National Institutes of
Health, Bethesda, MD).
Protein-G Binding Assay
The effect of proteases on the Fc region of TNF-
neutralizing agents was assessed by a protein-G binding
assay. Untreated or MMP3-/MMP12-treated TNF-neutralizing
agents were added to the wells of a protein-G–coated plate
(Fisher Scientific UK). Because chicken antibodies are unable
to bind to protein-G, chicken anti-human p75 TNF-receptor
antibody (Abcam), previously conjugated with horseradish
peroxidase using a commercial kit (Abcam), or horseradish
peroxidase–conjugated chicken anti-human F(ab’)2 (Fisher
Scientific UK), were added to it as a method to detect,
respectively, the amount of etanercept or infliximab and ada-
limumab bound to the plate. Tetramethylbenzidine then was
added and after stopping the reaction the optical density was
measured on a plate reader.
Luciferase Assay
The effect of proteases on the TNF-neutralizing function of
anti-TNF agents was assessed by means of a HeLa cell line,
which had been stably transfected with the luciferase reporter
gene under the control of nuclear factor-kB–enhancer ele-
ments.20 HeLa cells were cultured for 6 hours in the absence or
presence of 10 ng/mL recombinant human TNF (R&D Systems),
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mumab, or etanercept, all pre-incubated for 24 hours with
MMP activation buffer or active MMP3, MMP12, PBS, or
mucosal homogenates prepared in PBS. In parallel, the same
experiments were performed with the addition of the MMP
inhibitors marimastat (Sigma-Aldrich) or UK370106 (Santa
Cruz Biotechnology). The detailed description of experimental
conditions is reported in the Supplementary Materials and
Methods section. After culture, HeLa cells were lysated and
assayed for luciferase activity with a commercial kit (Pro-
mega UK, Southampton, UK), following the manufacturer’s
instructions, using a luminometer.
Clipped Endogenous IgG Detection
The presence of clipped endogenous IgG in IBD and HC sera
was assessed by a new enzyme-linked immunosorbent assay
(ELISA), by coating the plates with streptavidin (Sigma-
Aldrich), followed by incubation with biotinylated rabbit anti-
human MMP3/MMP12 IgG hinge cleavage site monoclonal
antibody (kindly provided by R. J. Brezski), then serial dilutions
of IBD and HC sera, followed by a horseradish peroxidase–
conjugated donkey anti-human IgG heavy- and light-chain
antibody (1:10,000; Jackson ImmunoResearch, West Grove,
PA). The detailed description of the ELISA is reported in the
Supplementary Materials and Methods section.
Antihinge Autoantibody Detection
Antihinge autoantibodies against the immunogenic neo-
epitopes generated by the proteolytic cleavage of endogenous
IgG were assessed in IBD and HC sera by a new ELISA, by
coating the plates with streptavidin (Sigma-Aldrich), followed
by incubation with 1 mmol/L biotinylated 14mer peptide
analogue of the human IgG1 hinge with a C-terminal amino acid
correspondent to the MMP3/MMP12 cleavage site (kindly
provided by R. J. Brezski), then serial dilutions of IBD and HC
sera, followed by a horseradish peroxidase–conjugated goat
anti-human IgG Fc antibody (1:10,000; Jackson Immuno-
Research). The detailed description of the ELISA is reported in
the Supplementary Materials and Methods section.
Statistics
Data were analyzed using the GraphPad Prism statistical PC
program (GraphPad Software, San Diego, CA) by means of
comparisons between groups using the Mann–Whitney U test
or the Student t test. A level of P < .05 was considered statis-
tically significant.
Results
Effect of MMP3, MMP12, and MMP9 on the
Integrity and Function of TNF-Neutralizing
Agents
We co-incubated increasing concentrations (0.001–1 mg/mL)
of MMP3 or MMP12, or 1 mg/mL MMP9 for 24 hours
with 1 mg/mL infliximab, adalimumab, and etanercept, and
analyzed cleavage patterns in reducing gels by immuno-
blotting using an anti-human IgG Fc antibody. Infliximab,
adalimumab, and etanercept were clipped in a
concentration-dependent manner by both MMP3 andMMP12, with the formation of a 32-kilodalton fragment
(Figure 1A), which likely corresponds to the Fc monomer
observed after MMP digestion of native human IgG1.
15 An
additional approximately 50-kilodalton etanercept fragment
appeared at low MMP concentrations. Densitometry of the
percentage of intact drug remaining at each concentration
showed that etanercept was markedly more susceptible to
clipping than infliximab and adalimumab (Figure 1B).
Treatment of each TNF-neutralizing agent with a fixed
concentration (1 mg/mL) of MMP3 or MMP12 and blotting
in nonreducing gels with anti-human immunoglobulin k
light chain showed that degradation of infliximab and ada-
limumab occurs in a time-dependent sequential manner,
with the formation of single-cleaved, upon removal of 1 Fc
monomer, and, subsequently, double-cleaved, F(ab’)2, in-
termediate products (Figure 1C). Etanercept could not be
visualized using anti-human immunoglobulin k primary
antibody. Infliximab, adalimumab, and etanercept were not
cleaved by MMP9 (Supplementary Figure 1).
We next performed an ELISA using protein-G–coated
plates as another way to look at loss of Fc. Untreated TNF-
neutralizing agents bound strongly to protein G, but after 24
hours of incubation with MMPs, binding decreased in a
dose-dependent fashion (Figure 2A). Etanercept binding
was minimal after MMP treatment.
We then investigated the effect of MMP3 and MMP12 on
the ability of biologic agents to neutralize soluble TNF. In
the absence of MMPs, infliximab, adalimumab, and eta-
nercept effectively inhibited TNF-induced luciferase activity
(Figure 2B). Neutralization of TNF by infliximab and adali-
mumab did not change after overnight incubation with
MMP3/MMP12, whereas etanercept showed a significant
reduction in its ability to neutralize TNF.Proteolytic Cleavage of TNF-Neutralizing Agents
by IBD Mucosal Proteins
We also prepared protein homogenates from normal HC
and inflamed IBD colonic mucosa, and we observed that IBD
protein extracts have significantly higher MMP3 and
MMP12 activity compared with HC homogenates
(Figure 3A). No significant correlation was found between
the degree of histologic inflammation in IBD biopsy speci-
mens and the level of MMP3 and MMP12 activity in paired
IBD homogenates. We subsequently co-incubated IBD and
HC homogenates with TNF-neutralizing agents. No cleavage
by HC homogenates was detected, whereas infliximab,
adalimumab, and etanercept were cleaved by IBD proteins
(Figure 3B), suggesting that the increased proteolytic ac-
tivity present in chronically inflamed tissues may affect drug
stability. Although infliximab and adalimumab were
partially cleaved, intact etanercept was completely lost after
co-incubation with IBD homogenates. In some cases we
could observe the 32-kilodalton fragment, indicative of
lower hinge cleavage by MMP3/MMP12 (Figure 3B, patient
2); nevertheless, the heterogeneous clipping profile between
different patients suggests that the tissue proteolytic profile
varies among individuals and other proteases also may con-
tribute to IgG cleavage. At low concentrations (0.1 mg/mL),
Figure 1. Degradation of TNF-neutralizing agents by MMP3 and MMP12. (A) Infliximab, adalimumab, and etanercept (1 mg/mL)
were co-incubated at 37C for 24 hours with increasing concentrations (0.001–1 mg/mL) of activated recombinant human
MMP3 or MMP12, and were visualized by immunoblotting in reducing conditions using an anti-human IgG Fc primary anti-
body. All TNF-neutralizing agents were cleaved by MMP3 or MMP12 with the formation of a 32-kilodalton band, likely to
correspond to the Fc monomer [Fc(m)] observed after MMP digestion of native human IgG1. Cleavage occurred in
a concentration-dependent manner, as shown by the increasing intensity of the 32-kilodalton band at higher MMP concen-
trations and the decreasing intensity of the bands correspondent to the intact heavy chain of infliximab and adalimumab and to
the intact etanercept monomer. Blots are representative of 6 separate experiments. (B) Densitometry of the intact infliximab
and adalimumab heavy chain, and of the intact etanercept monomer, after co-incubation with MMP3 or MMP12. Results are
the mean percentage of the intact drug after MMP treatment compared with the correspondent untreated TNF-neutralizing
agent ± SD (n ¼ 6). *P < .005 vs MMP3-/MMP12-treated etanercept at the correspondent MMP concentration.
(C) Infliximab and adalimumab, each at a concentration of 1 mg/mL, were co-incubated at 37C with 1 mg/mL activated
recombinant human MMP3 or MMP12. The incubation was interrupted at fixed time points (3, 6, 10, and 24 hours), and the
TNF-neutralizing agents were visualized by immunoblotting in nonreducing conditions using an anti-human immunoglobulin
k light-chain antibody. Infliximab and adalimumab were cleaved in a time-dependent manner by either MMP3 or MMP12 with
the sequential formation of 2 additional approximately 130- and approximately 100-kilodalton bands, which likely correspond
to the single-cleaved immunoglobulin intermediate (scIg) and F(ab’)2 fragments, respectively, and which increased in intensity,
in parallel with the fading of the bands correspondent to the intact drugs, over time. Blots are representative of 3 separate
experiments.
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ability to neutralize soluble TNF after co-incubation with
IBD proteins (Figure 3C). Etanercept largely lost its ability at
all doses to neutralize TNF after co-incubation with IBD
proteins. As expected, TNF concentration in both Crohn’s
disease and ulcerative colitis homogenates was significantlyhigher compared with HC homogenates, however, the mean
concentration of TNF in IBD homogenates was approximately
200 times lower than the concentration of exogenous TNF
used for HeLa cell stimulation (Supplementary Figure 2A).
Culture with IBD homogenates induced a small, not signifi-
cant, increase in luciferase production by HeLa cells, both in
Figure 2. Effect of MMP3 and MMP12 on protein-G binding capacity and TNF-neutralization function of anti-TNF agents.
(A) Untreated or MMP3- and MMP12-treated TNF-neutralizing agents were added to the wells of protein-G–coated plates.
Horseradish peroxidase–conjugated chicken anti-human F(ab’)2 or anti-human TNF-receptor II antibodies, which do not bind
to protein-G, were used to detect and quantify protein-G binding to TNF-neutralizing agents. Values, expressed as optical
density (OD), are mean ± SD of 6 separate experiments. *P < .01 vs etanercept at the corresponding MMP concentration.
#P < .005 vs etanercept at the corresponding MMP concentration. (B) Nuclear factor-kB reporter HeLa cells were cultured for
6 hours with TNF, with increasing concentrations (0.01–10 mg/mL) of infliximab, adalimumab, or etanercept, pre-incubated
for 24 hours with TCNB buffer (without MMPs), or 1 mg/mL active MMP3 or MMP12. After culture, HeLa cell lysates were
assayed for luciferase activity. Values, expressed as arbitrary units (a.u.), are means ± SD of 6 separate experiments. *P < .005
vs TNF plus TCNB-treated etanercept at the correspondent concentration.
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Figure 2B).Effect of MMP Inhibitors on Proteolytic Cleavage
of TNF-Neutralizing Agents
We then evaluated the effect of the broad-spectrum
MMP inhibitor marimastat or the selective MMP3/MMP12
inhibitor UK370106 on the function of TNF-neutralizing
agents exposed to MMPs or IBD mucosal proteins.
Although the addition of UK370106 to both MMP3 andMMP12 effectively restored TNF-neutralizing function of
etanercept in a dose-dependent manner, marimastat was
able to prevent only MMP3- but not MMP12-induced loss of
TNF-neutralizing ability of etanercept (Figure 4A).
Conversely, both marimastat and, to a lesser extent,
UK370106 were able to restore the ability of infliximab,
adalimumab, and etanercept to neutralize TNF on exposure
to IBD homogenates (Figure 4B). Neither marimastat nor
UK370106 had any effect on luciferase production by HeLa
cells, both in the absence and presence of exogenous TNF
(Supplementary Figure 2B).
Figure 3. Effect of mucosal homogenates on the integrity and function of TNF-neutralizing agents. (A) MMP3 and MMP12
activity in the homogenates of normal colonic mucosa of 8 HC subjects and inflamed colonic mucosa of 8 IBD patients. Bars
are mean ± SD. Active recombinant human (rh)MMP3 and rhMMP12 have been used as positive controls. *P < .01 vs IBD
mucosa, rhMMP3, and rhMMP12. (B) Infliximab, adalimumab, and etanercept, all at a concentration of 1 mg/mL, were co-
incubated for 24 hours with PBS only or with mucosal proteins from the colon of HC subjects or from the colon of IBD pa-
tients, and subsequently were visualized by immunoblotting in reducing conditions using an anti-human IgG Fc primary
antibody. The heavy chains of infliximab and adalimumab appeared as a single band of approximately 55 kilodaltons,
remained intact after 24 hours co-incubation with PBS or HC homogenates, and were partially cleaved by IBD mucosal ho-
mogenates with the appearance of 32-, approximately 35-, and approximately 40-kilodalton fragments. Etanercept, which was
minimally cleaved by HC homogenates, was cleaved completely by inflamed IBD homogenates with the formation of 32- and
approximately 40-kilodalton fragments. The 32-kilodalton band is consistent with lower-hinge cleavage. Blots are represen-
tative of experiments performed with colonic mucosal proteins from 6 HC subjects and 6 IBD patients. (C) Nuclear factor-kB
reporter HeLa cells were cultured with TNF, with or without increasing concentrations of infliximab, adalimumab, or etanercept,
all pretreated for 24 hours with either PBS or mucosal proteins from 8 HC subjects or 8 IBD patients. After culture, HeLa cell
lysates were assayed for luciferase activity. Values, expressed as arbitrary units (a.u.), are means ± SD of 8 separate ex-
periments. *P < .001 vs TNF plus PBS/HC-treated infliximab 0.1 mg/mL, vs TNF plus PBS/HC-treated adalimumab 0.1 mg/mL.
#P < .0005 vs TNF plus PBS/HC-treated etanercept at the corresponding concentration.
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Figure 4. Nuclear factor-kB reporter HeLa cells were cultured for 6 hours in the absence or presence of 10 ng/mL recombinant
human TNF, with (A) 0.1 mg/mL etanercept, pre-incubated for 24 hours with TCNB buffer or 1 mg/mL active MMP3 or MMP12
in the absence or presence of increasing concentrations (0.001–1 mmol/L) of marimastat or UK370106, or (B) 0.1 mg/mL
infliximab, adalimumab, or etanercept, all pretreated for 24 hours with either PBS or mucosal homogenates from 8 IBD patients
in the absence or presence of increasing concentrations (0.001–1 mmol/L) of marimastat or UK370106. After culture, HeLa cell
lysates were assayed for luciferase activity. Values, expressed as arbitrary units (a.u.), are means ± SD of (A) 6 and (B) 8
separate experiments. *P < .005 vs TNF plus MMP-treated etanercept and vs TNF plus the corresponding IBD-treated TNF-
neutralizing agent. #P < .05 vs TNF plus MMP-treated etanercept and vs TNF plus IBD-treated TNF-neutralizing agent.
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IgG and Antihinge Autoantibodies in IBD and
Control Sera
We next tried to detect clipped endogenous IgG in IBD
sera using an antibody specific for the MMP3 and MMP12
cleavage site on IgG. Sera from patients with active IBD
contained higher levels of cleaved endogenous IgG
compared with HC subjects (Figure 5A). This result was
confirmed by performing the assay using a range of
different serum dilutions (Supplementary Figure 3). Strati-
fication of IBD patients according to their response to bio-
logic therapy showed that nonresponders had significantly
higher serum levels of MMP3-/MMP12-cleaved IgG than
responders (Figure 5A). Clipped infliximab in IBD patient
sera collected immediately after the first infusion or before
the second infusion was undetectable.
Cleavage of endogenous IgG creates immunogenic neo-
epitopes and autoantibody production.21,22 Therefore, we
performed an ELISA on the same IBD and HC sera by coating
plates with the IgG hinge region peptide sequence generated
by MMP3/MMP12 cleavage. Sera from active IBD patients
contained higher concentrations of antihinge autoantibodiescompared with HC subjects (Figure 5B). Moreover, higher
levels of antihinge autoantibodies were found in the sera of
nonresponders (Figure 5B).Discussion
We show here that the proteases MMP3 and MMP12, but
not MMP9, cleave infliximab, adalimumab, and etanercept
in vitro in a dose-dependent manner. Mucosal homogenates
from inflamed IBD biopsy specimens impair the integrity
of infliximab, adalimumab, and etanercept. As a result
of proteolytic degradation, only etanercept loses its TNF-
neutralization ability. Sera from IBD patients who subse-
quently did not respond to biologic therapy contain higher
levels of MMP3-/MMP12-cleaved endogenous IgG and
antihinge autoantibodies.
Multiple factors contribute to nonresponsiveness to
biologic agents that neutralize TNF in IBD. In particular, the
formation of antidrug antibodies, especially against inflix-
imab, exerts a profound influence on the persistence of
functional TNF-neutralizing agents in the circulation and,
more importantly, in the inflamed mucosa.23,24 However,
Figure 5. Serum levels of MMP3-/MMP12-cleaved endogenous IgG and antihinge autoantibodies. ELISA plates were coated
with streptavidin, followed by (A) a biotinylated rabbit anti-human MMP3/MMP12 IgG hinge cleavage site monoclonal antibody
or (B) the biotinylated 14mer peptide analogue of the human IgG1 hinge with a C-terminal amino acid corresponding to the
MMP3/MMP12 cleavage site. Sera from 62 active IBD patients and from 20 HC subjects were serially diluted and added to the
plate, then (A) a horseradish peroxidase–conjugated donkey anti-human IgG heavy- and light-chain antibody or (B) a
horseradish peroxidase–conjugated goat anti-human IgG Fc antibody were used to detect bound cleaved IgG or antihinge
autoantibodies. Levels of clipped endogenous IgG are expressed as optical density (OD). For antihinge autoantibodies, a
concentration curve was constructed based on the OD recorded for the standard (a chimeric rabbit/human anti-human MMP3/
MMP12 IgG hinge cleavage site monoclonal antibody), and the corresponding equation was used to convert the serum
antihinge autoantibody OD into ng/mL. IBD patients were stratified as responders (IBD resp; n ¼ 46) or nonresponders (IBD
non-resp; n ¼ 16; 6 Crohn’s disease and 10 ulcerative colitis patients) according to their subsequent response to infliximab
treatment. Data shown here were obtained at a (A, left panel) 1:50 or a (A, right panel); (B) 1:1350 dilution of the sera. (A) *P <
.005 vs HC sera. **P < .05 vs IBD resp sera. (B) *P < .05 vs HC sera. **P < .05 vs IBD resp sera.
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phase and are unlikely to play a role in primary nonre-
sponse. Our results suggest that proteolytic degradation
occurring at the site of inflammation may be a novel
mechanism affecting the bioavailability of TNF-neutralizing
agents and contributing to primary nonresponsiveness in
IBD. Human IgG2 are resistant to proteolytic cleavage by
MMPs, however, their Fc-dependent cell killing functions are
weak.25 Specific mutations can be incorporated into the Fc
region of protease-resistant monoclonal IgG1 antibodies,
resulting in enhanced cell killing properties.18 Therefore, it
may be possible to apply the same strategy to generate TNF-
neutralizing agents resistant to proteolytic cleavage without
compromising their immunologic properties.
Similarly to what has been shown for the monoclonal
antibodies trastuzumab and rituximab,26 the presence of the
Fc region is necessary for some important immunologic
properties of TNF-neutralizing agents, such as antibody-
dependent, cell-mediated cytotoxicity and complement
activation.3 A genetic polymorphism in IgG Fc receptor IIIa
that enhances its affinity for IgG1 is associated with an
increased biological response to infliximab in Crohn’s dis-
ease.27 Moreover, Vos et al28,29 showed that the Fc region isrequired for the ability of TNF-neutralizing monoclonal
antibodies to promote the development of regulatory M2
macrophages, which are induced by infliximab in responder,
but not in nonresponder, IBD patients. We have observed
that proteolytic digestion by MMP3 and MMP12 leads to the
complete removal of the Fc region of TNF-neutralizing
agents. As a result, despite infliximab and adalimumab still
being able to neutralize soluble TNF as F(ab’)2 fragments
even at the lowest anti-TNF/MMP concentration ratio of
1:10, proteolytic degradation of TNF-neutralizing agents is
likely to be clinically relevant in vivo in IBD patients
because of the consequent impairment of Fc-mediated
properties. Moreover, because binding of the IgG to the
neonatal Fc receptor has been shown to protect them from
catabolism,30 the removal of the Fc region from anti-TNF
agents operated by MMPs may result in decreased serum
trough levels of these drugs.
In our in vitro experiments we only studied MMP3,
MMP12, and MMP9, and we have not assessed the effects of
a range of other proteases with known ability to cleave IgG,
including MMP7, MMP13, and the serine proteases elastase
and cathepsin G,15,16 which are likely to play a relevant role
in biologic agent clipping in vivo. Moreover, in our
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time and do not know if these reflect the in vivo situation, in
which there is continuing production of MMPs by activated
fibroblasts and inflammatory cells into the pericellular
spaces.31 The multiple bands detected after incubation of
adalimumab and infliximab with IBD mucosal proteins did
not correspond to the 32-kilodalton band seen with re-
combinant MMPs, suggesting that, in the complex situation
of inflammation, clipping of biologic agents may be variable
in different patients. Our observations on the effects of IBD
mucosal proteins on anti-TNF agents in the absence or
presence of MMP inhibitors suggest that proteolytic cleav-
age in the inflamed tissue may influence the efficacy of TNF-
neutralizing agents, however, in the present study we have
not examined our hypothesis by means of in vivo experi-
ments. This instead could be the focus of a future preclinical
interventional study on the treatment of experimental colitis
with anti-TNF antibodies combined with the broad-
spectrum MMP inhibitor marimastat. Although this
approach would not provide clear evidence that MMP3 and
MMP12 are the key enzymes involved in proteolytic
degradation, it will be useful to evaluate whether MMP in-
hibition may enhance the efficacy of anti-TNF therapy.
Our findings provide an explanation for the failure of
etanercept in Crohn’s disease,7 which is very susceptible to
proteolytic cleavage and the only one drug to substantially
lose its TNF-neutralizing ability after Fc removal by MMP3/
MMP12 and IBD mucosal proteins. This may be related to a
conformational change in the p75 TNF receptor when
cleaved from the IgG tail. On the other hand, etanercept is
clinically useful in rheumatoid arthritis,8 and there are many
reports showing that MMP3 is increased in the rheumatoid
joint.10 However, the concentration and activity of MMPs
and their natural inhibitors in the affected tissues may be
different in different diseases; therefore, local quantification
of proteolytic activity would be important for interpretation
of our results and translation into practical consequences. In
more fulminant diseases, such as IBD, cleavage and loss of
function of biologic agents may be quantitatively greater
than in the rheumatoid joint. The high susceptibility of
etanercept to proteolytic cleavage suggests that there may
be an inherent problem with Fc-receptor fusion proteins at
sites of inflammation rich in proteases. The recent failure of
the cytotoxic T-lymphocyte-associated protein (CTLA)-4
fusion protein abatacept both in Crohn’s disease and in
ulcerative colitis32 supports this idea.
We tried to detect clipped infliximab in IBD patient sera
collected immediately after the first infusion or before the
second infusion, however, these experiments uniformly
were negative. This may be owing to the low ratio of clipped
vs intact drug within the sera collected 1 hour after the
infusion, or to the catabolism of degraded IgG in the samples
collected before the following administration. An additional
reason may be the fact that the F(ab’)2 fragments generated
as a result of proteolytic cleavage become self-antigens that
are recognized by autoantibodies,21 which may prevent the
possibility of detecting clipped infliximab with an immu-
noassay directed against the same epitope. Interestingly,
patients with rheumatoid arthritis have a higher incidenceof serum antihinge autoantibodies compared with HC sub-
jects.22 We performed an ELISA on IBD and HC sera by
coating the plate with the peptide sequence on the IgG hinge
region generated by MMP3/MMP12 cleavage. Sera from
active IBD patients contained significantly higher concen-
trations of antihinge autoantibodies compared with HC
subjects. We then stratified IBD patients according to their
response to biologic therapy, and we observed that patients
who subsequently did not respond to treatment had
significantly higher levels of antihinge autoantibodies than
responders. Moreover, sera from active IBD patients and
nonresponder IBD patients contained significantly higher
serum levels of MMP3-/MMP12-cleaved endogenous IgG
than HC subjects and responders.
Therapeutic drug monitoring by serial measurement of
serum trough levels of anti-TNF agents is a valuable strategy
for optimizing the management of nonresponsiveness to
biologic therapy in IBD.33–35 However, there is a strong need
for biomarkers able to stratify IBD patients according to
their subsequent possibility to respond to biologic therapy.36
The evaluation of mucosal proteolytic potential through the
quantification of serum levels of cleaved IgG and antihinge
autoantibodies opens the possibility of developing a
biomarker of responsiveness to biologic therapy in IBD. In
addition, our results may contribute to clarifying the mech-
anisms underlying primary nonresponse to TNF-neutralizing
agents, especially in severely active IBD patients who are
likely to have high mucosal proteolytic activity and therefore
may benefit from a higher anti-TNF loading dose.37Supplementary Material
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Supplementary Materials and Methods
Cleavage Reactions
Upon activation, recombinant human MMP3, MMP12,
and MMP9 (R&D Systems) were co-incubated with TNF-
neutralizing agents to subsequently evaluate their effect
on the drug integrity and function. Recombinant human
pro-MMP3 and pro-MMP9 (both from R&D Systems) were
activated by 24-hour incubation at 37C with p-amino-
phenylmercuric acetate (Sigma-Aldrich) 1 mmol/L in 50
mmol/L Tris, 10 mmol/L CaCl2, 150 mmol/L NaCl, 0.05%
Brij 35 (Sigma-Aldrich) (TCNB) buffer, whereas recombi-
nant human pro-MMP12 (R&D Systems) was auto-activated
by 30-hour incubation at 37C in TCNB buffer, following
the manufacturer’s instructions. Infliximab (Remicade;
Schering-Plough), adalimumab (Humira; Abbott Labora-
tories), or etanercept (Enbrel; Wyeth), each one at a con-
centration of 1 mg/mL, were incubated for 24 hours at 37C
with active MMP3, active MMP12 (0.001–1 mg/mL), active
MMP9 (1 mg/mL), or p-aminophenylmercuric acetate 0.02
mmol/L in TCNB buffer or TCNB buffer alone. In parallel,
infliximab, adalimumab, or etanercept, each one
at a concentration of 1 mg/mL, were incubated for 24 hours
at 37C with 1 mg/mL active MMP3, MMP12, or p-amino-
phenylmercuric acetate 0.2 mmol/L in TCNB buffer or TCNB
buffer alone, and the reaction was stopped at fixed time
points (3, 6, 10, and 24 h). In parallel, increasing concen-
trations (0.01–10 mg/mL) of infliximab, adalimumab, or
etanercept were co-incubated for 24 hours with p-amino-
phenylmercuric acetate 0.02 mmol/L in TCNB buffer or 1
mg/mL active MMP3 or MMP12. In parallel, etanercept 0.1
mg/mL was incubated for 24 hours at 37C with 1 mg/mL
active MMP3 or MMP12 or p-aminophenylmercuric acetate
0.2 mmol/L in TCNB buffer or TCNB buffer alone, in the
absence or presence of increasing concentrations (0.001–1
mmol/L) of marimastat (Sigma-Aldrich) or UK370106 (Santa
Cruz Biotechnology). Moreover, to assess the effect of
mucosal protein extracts on TNF-neutralizing agents, inflix-
imab, adalimumab, and etanercept, all at a concentration of 1
mg/mL, were co-incubated for 24 hours with either PBS only
or with mucosal homogenates. In parallel, increasing con-
centrations (0.01–10 mg/mL) of infliximab, adalimumab, or
etanercept were co-incubated for 24 hours with either PBS
only or with mucosal homogenates. In parallel, infliximab,
adalimumab, and etanercept, all at a concentration of 0.1 mg/
mL, were incubated for 24 hours at 37C with either PBS
only or with IBD mucosal homogenates, in the absence or
presence of increasing concentrations (0.001–1 mmol/L) of
marimastat (Sigma-Aldrich) or UK370106 (Santa Cruz
Biotechnology). Cleavage reaction products then were
stored at -70C until further analysis.
TNF Detection in Mucosal Homogenates
The TNF concentration in the homogenates from colonic
mucosa of HC and IBD patients was measured using the
Human TNF DuoSet ELISA kit (R&D Systems), according to
the manufacturer’s instructions.
Luciferase Assay
The effect of proteases on the TNF-neutralizing function
of anti-TNF agents was assessed by means of a HeLa cell
line that had been stably transfected with the luciferase
reporter gene under the control of nuclear factor-kB
enhancer elements. HeLa cells were cultured for 6 hours in
the absence or presence of 10 ng/mL recombinant human
TNF (R&D Systems), with or without 1 mg/mL active MMP3
or MMP12 or increasing concentrations (0.01–10 mg/mL) of
infliximab, adalimumab, or etanercept, all pretreated for 24
hours with either p-aminophenylmercuric acetate 0.02
mmol/L in TCNB buffer or 1 mg/mL active MMP3 or
MMP12. In parallel, HeLa cells were cultured in the absence
or presence of 10 ng/mL recombinant human TNF, with 0.1
mg/mL etanercept, preincubated for 24 hours with TCNB or
1 mg/mL active MMP3 or MMP12, in the absence or pres-
ence of increasing concentrations (0.001–1 mmol/L) of
marimastat (Sigma-Aldrich) or UK370106 (Santa Cruz
Biotechnology). In parallel, HeLa cells were cultured with
10 ng/mL recombinant human TNF, with or without
increasing concentrations (0.01–10 mg/mL) of infliximab,
adalimumab, or etanercept, all pretreated for 24 hours with
either PBS or mucosal homogenates prepared in PBS. In
parallel, HeLa cells were cultured for 6 hours in the absence
or presence of 10 ng/mL recombinant human TNF, with or
without 0.1 mg/mL of infliximab, adalimumab, or eta-
nercept, all pretreated for 24 hours with either PBS or
mucosal proteins from IBD patients, in the absence or
presence of increasing concentrations (0.001–1 mmol/L) of
marimastat (Sigma-Aldrich) or UK370106 (Santa Cruz
Biotechnology). The direct effect of IBD homogenates and
MMP inhibitors on the production of luciferase by HeLa
cells also was assessed. HeLa cells were cultured for 6 hours
in the absence or presence of 10 ng/mL recombinant hu-
man TNF (R&D Systems), with or without IBD mucosal
homogenates prepared in PBS, in the absence or presence of
1 mmol/L marimastat (Sigma-Aldrich) or 1 mmol/L
UK370106 (Santa Cruz Biotechnology).
After culture, HeLa cells were lysated and assayed for
luciferase activity with a commercial kit (Promega UK),
following the manufacturer’s instructions, using a
luminometer.
Clipped Infliximab Detection
We tried to detect clipped infliximab in human sera of
IBD patients by a new ELISA. Recombinant human TNF
(R&D Systems) 10 mg/mL was added to Nunc Clear Max-
isorp 96-well plates (Sigma-Aldrich). After overnight incu-
bation at þ4C, plates were blocked for 30 minutes at room
temperature in 3% bovine serum albumin (Sigma-Aldrich)
in PBS. Serial dilutions of IBD sera, and of MMP3- and
MMP12-cleaved infliximab (kindly provided by R. J. Brezski,
starting from 2 mg/mL), which we used as standard, were
added to the plates. After 1 hour at room temperature, 2.5
mg/mL biotinylated rabbit anti-human MMP3/MMP12 IgG
hinge cleavage site monoclonal antibody (kindly provided
by R. J. Brezski) was added. After 1 hour at room temper-
ature, horseradish peroxidase–conjugated streptavidin
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(R&D Systems) 1:10,000 was added to the plates. After 1
hour and thorough washing, tetramethylbenzidine was
added, and after stopping the reaction the optical density
was measured on a plate reader.
Clipped Endogenous IgG Detection
The presence of clipped endogenous IgG in human
sera of IBD patients and HC subjects was assessed by a
new ELISA. Streptavidin (Sigma-Aldrich) 10 mg/mL was
added to Nunc Clear Maxisorp 96-well plates (Sigma-
Aldrich). After overnight incubation at þ4C, plates were
blocked for 30 minutes at room temperature in 3%
bovine serum albumin (Sigma-Aldrich) in PBS, and then
incubated for 1 hour at room temperature with 15 mg/mL
biotinylated rabbit anti-human MMP3/MMP12 IgG hinge
cleavage site monoclonal antibody (kindly provided by
R. J. Brezski). Plates then were incubated for 1 hour at
room temperature with serial dilutions of IBD and HC
sera, followed by a horseradish peroxidase–conjugated
donkey anti-human IgG heavy- and light-chain antibody
(1:10,000; Jackson ImmunoResearch), that has minimum
cross-reactivity with rabbit IgG. After 1 hour and thor-
ough washing, tetramethylbenzidine was added, and after
stopping the reaction the optical density was measured
on a plate reader.
Antihinge Autoantibody Detection
Antihinge autoantibodies against the immunogenic neo-
epitopes generated by the proteolytic cleavage of endoge-
nous IgG were assessed in IBD and HC sera by a new ELISA.
Streptavidin (Sigma-Aldrich) 10 mg/mL was added to Nunc
Clear Maxisorp 96-well plates (Sigma-Aldrich). After over-
night incubation atþ4C, plates were blocked for 30minutes
at room temperature in 3% bovine serum albumin (Sigma-
Aldrich) in PBS, and then incubated for 1 hour at room tem-
peraturewith 1mmol/L biotinylated 14mer peptide analogue
of the human IgG1 hinge with a C-terminal amino acid cor-
responding to the MMP3/MMP12 cleavage site (kindly pro-
vided by R. J. Brezski). Plates then were incubated for 1 hour
at room temperature with serial dilutions of a chimeric
rabbit/human anti-human MMP3/MMP12 IgG hinge cleav-
age site monoclonal antibody, which we used as a standard,
or IBD and HC sera, followed by a horseradish perox-
idase–conjugated goat anti-human IgG Fc antibody
(1:10,000; Jackson ImmunoResearch). After 1 hour and
thorough washing, tetramethylbenzidine was added, and af-
ter stopping the reaction the optical densitywasmeasured on
a plate reader. A concentration curve was constructed based
on the optical densities recorded for the standard, and the
correspondent equation allowed conversion of serum anti-
hinge autoantibody optical densities into ng/mL.
Supplementary Figure 1. Effect of MMP9 on the integrity of TNF-neutralizing agents. Infliximab, adalimumab, and etanercept
(1 mg/mL) were co-incubated at 37C for 24 hours with 1 mg/mL of activated recombinant human MMP9, and visualized by
immunoblotting in reducing conditions using an anti-human IgG Fc primary antibody. Infliximab, adalimumab, and etanercept
were not cleaved by MMP9. Blots are representative of 6 separate experiments.
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Supplementary Figure 2. (A) Concentration of TNF, expressed as pg/mL, in the homogenates of normal colonic mucosa of 8
HC subjects and from inflamed colonic mucosa of 16 IBD patients (ulcerative colitis [UC], n ¼ 8; Crohn’s disease [CD], n ¼ 8).
Bars are mean values. *P < .0005 vs HC homogenates. (B) Nuclear factor-kB reporter HeLa cells were cultured for 6 hours in
the absence or presence of 10 ng/mL recombinant human TNF, with or without mucosal homogenates from 8 IBD patients, in
the absence or presence of 1 mmol/L marimastat or 1 mmol/L UK370106. After culture, HeLa cell lysates were assayed for
luciferase activity. Values, expressed as arbitrary units (a.u.), are means ± SD of 8 separate experiments. No significant dif-
ference was observed between culture with or without MMP inhibitors. No significant difference was observed between culture
with PBS or with IBD homogenates. *P < .0001 vs the corresponding condition without TNF.
Supplementary Figure 3. Levels of MMP3-/MMP12-cleaved endogenous IgG in active IBD patients compared with HC
subjects, determined using a range of different serum dilutions. Sera from 62 active IBD patients and from 20 HC subjects
were serially diluted from 1:50 down to 1:12,150 and added to the plate. Levels of clipped endogenous IgG are expressed as
optical density (OD). Horizontal bars indicate the mean OD.
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